

*2021 CTOS Virtual Annual Meeting  
SARC Semiannual Meeting Agenda  
Thursday, November 11, 2021; 3:30 – 5:30 pm ET*

Chawla-Rosenfeld Developmental Therapeutics Symposium: 3:30-4:50 pm ET	
<b>Sarcoma Origins: Predisposition and Precursors</b>	
Introduction	<b><u>Jonathan Fletcher, MD</u></b> (SARC CSO) Brigham and Women's Hospital - DF/HCC
Mapping and management of genetic risk in the sarcoma population	<b><u>David Thomas, FRACP, PhD</u></b> Garvan Institute of Medical Research
LMS oncogenesis: from tumor cells to normal cells	<b><u>Elodie Darbo, PhD</u></b> University of Bordeaux
Advances in early detection of malignant transformation of peripheral nerve sheath tumors in NF1	<b><u>Brigitte Widemann, MD</u></b> National Cancer Institute
Panel Discussion / Q & A <ul style="list-style-type: none"> <li>• David Thomas, FRACP, PhD</li> <li>• Elodie Darbo, PhD</li> <li>• Frédéric Chibon, PhD (CRCT-ONCOPOLE)</li> <li>• Brigitte Widemann, MD</li> </ul>	<b>Moderators:</b> <b><u>Joshua Schiffman, MD</u></b> Huntsman Cancer Institute <b><u>Irene Andrulis, PhD</u></b> University of Toronto
Closing Comments	<b><u>Jonathan Fletcher, MD</u></b> (SARC CSO)
SARC Research Initiatives: 4:50-5:30 pm ET	
<b>Introduction: Currently Enrolling SARC Clinical Trials</b>	<b><u>Scott Okuno, MD</u></b> (SARC Medical Officer) Mayo Clinic
<b>SARC037:</b> Phase I Trabectedin in Ewing Sarcoma in Combination with Irinotecan and 18F-FLT Imaging	<b>PI: <u>Patrick Grohar, MD, PhD</u></b> Children's Hospital of Philadelphia
<b>SARC031:</b> Phase 2 MEK inhibitor selumetinib w/ dual mTOR kinase inhibitor sirolimus in MPNST	<b>PI: <u>AeRang Kim, MD, PhD</u></b> Children's National Medical Center
<b>SARC032:</b> Phase 2 Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Soft Tissue Sarcoma of the Extremity	<b>PI: <u>David Kirsch, MD, PhD</u></b> Duke University
<b>SARC038:</b> Phase 2 Regorafenib in Combination with Nivolumab in Osteosarcoma	<b>Co-PI: <u>Lara Davis, MD</u></b> Oregon Health Sciences University
<b>SARC041:</b> Phase 3 Randomized Double-Blind Study of Abemaciclib vs. Placebo in Advanced DDLPS	<b>PI: <u>Mark Dickson, MD</u></b> Memorial Sloan-Kettering Cancer Center
SARC Principal Investigators / Q & A	<b>Moderators &amp; Closing Remarks:</b> <b><u>Jonathan Fletcher, MD</u></b> (SARC CSO)
SARC Scientific & Operational Strategies: ≥2022	<b><u>Steven Young</u></b> (SARC President & CEO)
<b>5:30 ET</b>	<b>Adjourn</b>